Press releases
Browse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
GSK and Theravance announce results of two pivotal Phase III studies for Relovair in COPD
GSK and THRX announced the results of two pivotal 6-month efficacy and safety phase III studies of Relovair for patients with COPD.
-
GSK forms partnership with three leading NGOs to address shortage of frontline healthcare workers in Least Developed Countries LDCs
- Agreements signed with AMREF, CARE International UK and Save the Children as part of commitment to reinvest 20% of profits in LDCs
-
GlaxoSmithKline and Human Genome Sciences receive positive opinion in Europe from the CHMP for Benlysta® belimumab
GSK & HGS announced that EMA's CHMP issued a positive opinion, recommending marketing authorisation for Benlysta, a lupus therapy.
-
Young peoples health charity steps forward to claim top accolade and 35,000
Step Forward, has beaten more than 400 organisations from around the UK to be crowned the overall winner of this year's GSK IMPACT Awards
-
pharmaceutical industry and university create manchester collaborative centre for inflammation research
GSK, UofM & AZN announce creation of MCCIR, unique collaboration to establish a world-leading translational centre for inflammatory diseases
-
GSK Q1 performance demonstrates continued progress with delivery of underlying sales growth, cash generation and pipeline visibility
Reported sales -10%; underlying sales* +4% EPS before major restructuring* 32.2p (+9%); dividend 16p (+7%)
-
Regulatory update – GSK and Valeant respond to FDA on ezogabine
GSK & VRX submitted on 15/04/11 the response to the FDA Complete Response letter received on 30 November 2010 for the NDA for ezogabine.
-
GSK welcomes key agreement to support global preparedness against pandemic influenza
GSK welcomes agreement reached at OEWG coordinated by WHO on a Framework to support global preparedness for a future influenza pandemic.
-
GSK European regulatory update on Pandemrix™
EMA's CHMP recommends changes to Pandemrix, including prescribing advice based on increased risk of narcolepsy in children or adolescents
-
Regulatory Update - Tyverb® lapatinib
GSK submitted a MAA to EMA for lapatinib in with paclitaxel for the treatment of metastatic breast cancer with over-express HER2 (ErbB2).
-
GlaxoSmithKline announces non-core OTC products to be divested
GSK to divest non-core OTC brands as it focuses Consumer Healthcare business around fast-growing priority brands and the emerging markets.
-
Unique research alliance expands collaboration opportunities at state-of-the-art medical imaging centre
UK research community to have access to world-class medical imaging facilities in London with the signing of an agreement between MRC & GSK
-
GlaxoSmithKline and XenoPort receive FDA approval for Horizant™
GSK & XNPT announced that the FDA has approved Horizant for the treatment of moderate-to-severe primary Restless Legs Syndrome in adults.
-
GSK publishes payments for research consulting and advising by US healthcare professionals
GSK published a list of payments for clinical research studies led by U.S. healthcare professionals, for the discovering of new medicines.
-
GlaxoSmithKline confirms Pronova BioPharma reaches agreement with Apotex regarding Lovaza™ US patent litigation
GSK confirmed that Pronova entered into an agreement with Apotex to settle their patent litigation in the United States related to Lovaza.
-
GSK and Valeant receive European authorisation for Trobalt (retigabine)
GSK & VRX announced, EC has granted marketing authorisation for Trobalt (retigabine) as an add-on treatment of partial onset seizures.
-
GSK publishes 2010 Corporate Responsibility Report
In its CRR, GSK reiterated its commitment to building its business on strong values and ethical standards.
-
GSK statement on Avodart™ (dutasteride) for prostate cancer risk reduction
GSK announced it will no longer pursue global approval for the use of Avodart (dutasteride) to reduce the risk of prostate cancer.
-
GSK launches London 2012 initiative with King’s College London to inspire young people into science careers
Scientists in Sport programme designed to inspire young people published a study that 8/10 secondary school pupils are worried about work.
-
GSK supports recovery efforts to help those affected by the Japan earthquake
As a result of the Tohoku Kanto Earthquake and tsunami GSK is supporting the ongoing relief efforts and pharmaceutical donation needs.